Investigational Drug Information for Seltorexant
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the drug development status for Seltorexant?
Seltorexant is an investigational drug.
There have been 18 clinical trials for Seltorexant.
The most recent clinical trial was a Phase 2 trial, which was initiated on September 15th 2020.
The most common disease conditions in clinical trials are Depressive Disorder, Major, Depressive Disorder, and Depression. The leading clinical trial sponsors are Janssen Research & Development, LLC, Minerva Neurosciences, and [disabled in preview].
There are four US patents protecting this investigational drug and eighty-nine international patents.
Summary for Seltorexant
| US Patents | 4 |
| International Patents | 89 |
| US Patent Applications | 18 |
| WIPO Patent Applications | 3 |
| Japanese Patent Applications | 1 |
| Clinical Trial Progress | Phase 2 (2020-09-15) |
| Vendors | 15 |
Recent Clinical Trials for Seltorexant
| Title | Sponsor | Phase |
|---|---|---|
| A Study of Seltorexant in Participants With Probable Alzheimer's Disease | Janssen Research & Development, LLC | Phase 2 |
| A Study of JNJ-42847922 (Seltorexant) in Healthy Participants | Janssen Research & Development, LLC | Phase 1 |
| A Study to Determine the Abuse Potential of Seltorexant Compared to Suvorexant and Zolpidem | Janssen Research & Development, LLC | Phase 1 |
Clinical Trial Summary for Seltorexant
Top disease conditions for Seltorexant
Top clinical trial sponsors for Seltorexant
US Patents for Seltorexant
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Seltorexant | See Plans and Pricing | Methods of treating depression using orexin-2 receptor antagonists | Janssen Pharmaceutica NV (Beerse, BE) | See Plans and Pricing |
| Seltorexant | See Plans and Pricing | Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators | Janssen Pharmaceutica (BE) | See Plans and Pricing |
| Seltorexant | See Plans and Pricing | Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators | Janssen Pharmaceutica NV (BE) | See Plans and Pricing |
| Seltorexant | See Plans and Pricing | Disubstituted octahydropyrrolo [3,4-C] pyrroles as orexin receptor modulators | Janssen Pharmaceutica NV (Beerse, BE) | See Plans and Pricing |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Seltorexant
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Seltorexant | Australia | AU2017231828 | 2036-03-10 | See Plans and Pricing |
| Seltorexant | Brazil | BR112018067906 | 2036-03-10 | See Plans and Pricing |
| Seltorexant | Canada | CA2960253 | 2036-03-10 | See Plans and Pricing |
| Seltorexant | Canada | CA3016706 | 2036-03-10 | See Plans and Pricing |
| Seltorexant | Chile | CL2018002533 | 2036-03-10 | See Plans and Pricing |
| Seltorexant | China | CN108883110 | 2036-03-10 | See Plans and Pricing |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
